Table 4

Annual rate of decline in FVC Z-score percent predicted FVC 2 years prior to the start of nusinersen compared with the first year of treatment

Rate of decline in FVC Z-score (mean; 95% CI) per annum
Prior to treatmentP valuePost treatmentP valueDifference between pretreatment and post-treatment rate of declineP value
Total group
(n=20)
−0.58 (−0.75 to −0.41) <0.001 −0.25 (−0.46 to −0.03) 0.02 0.33 (0.02 to 0.66) 0.04
SMA type 2
(n=12)
−0.61 (−0.77 to −0.44) <0.001 −0.08 (−0.32 to 0.15)0.480.52 (0.19 to 0.86) 0.002
SMA type 3
(n=8)
−0.61 (−1.09 to −0.12) 0.01 −0.50 (−0.91 to −0.09) 0.02 0.11 (−0.63 to 0.85)0.77
Rate of decline in percent predicted FVC (mean; 95% CI) per annum
2 years prior to treatmentP valueDuring first year of treatmentP valueDifference between pretreatment and post-treatment rate of declineP value
Total group
(n=20)
−5.94 (−7.74 to −4.14) <0.001 −2.56 (−4.82 to −0.30) 0.03 3.38 (−0.02 to 6.78) 0.05
SMA type 2
(n=12)
−5.86 (−7.60 to −4.11) <0.001 −1.03 (−3.55 to 1.50)0.424.83 (1.20 to 8.47) 0.009
SMA type 3
(n=8)
−7.69 (−12.71 to −2.67) 0.003 −4.75 (−9.01 to −0.49) 0.03 2.94 (−4.70 to 10.59)0.45
  • .

  • SMA, spinal muscular atrophy.